News brief­ing: Re­gen­eron/Sanofi post pos­i­tive PhI­II Dupix­ent da­ta in pe­di­atric asth­ma; Vineti scores $33M Se­ries C ...

5 years ago
News Briefing

Months af­ter re­tir­ing from Genen­tech, Michael Var­ney brings his drug hunt­ing eye to Fra­zier

5 years ago
People
Financing

A ma­jor new in­vestor just ar­rived at the biotech par­ty, as Evotec nets $295M from Mubadala and No­vo

5 years ago
Financing
Deals

Gos­samer shares take an­oth­er beat­ing as its lead drug fails 2 key clin­i­cal stud­ies, high­light­ing harsh re­views for ...

5 years ago
R&D

Out to pi­o­neer gene edit­ing in Chi­na, Edi­Gene bags $67M to be­gin clin­i­cal test­ing for β-tha­lassemia ther­a­py, ...

5 years ago
Financing
China

Rid­ing a PhII suc­cess, a small French biotech lands a rare 'break­through' sta­tus in NASH

5 years ago
R&D
FDA+

Covid-19 roundup: Vaxart dos­es first pa­tient in new clin­i­cal vac­cine study; NI­AID launch­es study to find po­ten­tial ...

5 years ago
Coronavirus

An­oth­er safe­ty in­ci­dent trig­gers a halt to a piv­otal Covid-19 vac­cine study as J&J slams on the brakes

5 years ago
Coronavirus

GSK's Em­ma Walm­s­ley grant­ed dame­hood by Queen Eliz­a­beth II

5 years ago
People

Voy­ager shares take a hit as FDA slaps a hold on the IND for Hunt­ing­ton's gene ther­a­py — their #2 play in the ...

5 years ago
Cell/Gene Tx
FDA+

Bob Langer-backed spin­out shoots for $75M-plus IPO while biotech SPACs con­tin­ue to rule on Wall Street

5 years ago
Financing
R&D

News brief­ing: Gilead re­veals more fil­go­tinib da­ta; Seagen and Astel­las re­port new co­hort for Pad­cev

5 years ago
News Briefing

Em­bat­tled Har­vard sci­en­tist Charles Lieber goes on a counter-of­fen­sive, hir­ing high-pro­file lawyer and su­ing Har­vard ...

5 years ago
People

Lil­ly shows more pos­i­tive Crohn's da­ta for its IL-23 in­hibitor as it con­tin­ues to chase down ri­vals

5 years ago
R&D

No­var­tis vets get $35M to pluck one of the phar­ma gi­ant’s aban­doned drugs off the shelf and put it back in­to a ...

5 years ago
Financing
R&D

Sa­mi An­war raked in mil­lions of dol­lars gath­er­ing drug tri­al da­ta at his sites. But it was all a lie — and now he's ...

5 years ago
People
Pharma

Drown­ing in lit­i­ga­tion, Mallinck­rodt be­comes third opi­oid pro­duc­er to file for bank­rupt­cy

5 years ago
Pharma

Alk­er­mes like­ly head­ed for ap­proval af­ter ad­comm waves through schiz­o­phre­nia and bipo­lar pro­gram

5 years ago
FDA+

Covid-19 roundup: Pfiz­er strikes vac­cine deal with New Zealand, as CEO Al­bert Bourla de­fends de­vel­op­ment rush to ...

5 years ago
Coronavirus

FDA sends small biotech and its re­for­mu­lat­ed pain med pack­ing, trig­ger­ing a col­lapse in the share price

5 years ago
FDA+

As­traZeneca gets a $500M an­ti­body con­tract, yet key ques­tions still loom for Trump's new fa­vorite treat­ment

5 years ago
Coronavirus

The oust­ed spokesper­son that Stephen Hahn re­moved? FDA says she’s still an ap­pointee, but won’t say what she does

5 years ago
FDA+

Park­er In­sti­tute sum­moned the neoanti­gen pi­o­neers to com­pare their pre­dic­tion al­go­rithms. And they have some ...

5 years ago
Discovery

Brett Zbar to lead life sci­ences in­vest­ing at Gen­er­al At­lantic; Michael Ka­vanaugh plans re­tire­ment as Cy­tomX pro­motes ...

5 years ago
Peer Review
First page Previous page 791792793794795796797 Next page Last page
A service from the Financial Times